Mitiglinide

From Wikipedia, the free encyclopedia

Mitiglinide
Systematic (IUPAC) name
(-)-2(S)-Benzyl-4-(cis-perhydroisoindol-2-yl)butyric acid
Identifiers
CAS number	207844-01-7
ATC code	A10BX
PubChem	121891
Chemical data
Formula	C19H25NO3
Mol. mass	315.41 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	oral

Mitiglinide (trade name Glufast®) is a drug for the treatment of type 2 diabetes.

Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

[edit] Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.

[edit] Dosage

Mitiglinide is delivered in tablet form.

[edit] External links

• Elixir Pharmaceuticals - website of the U.S. rights holder for mitiglinide.

v • d • e Oral antidiabetic drugs (A10B)
Biguanides	Metformin
Sulfonylureas	Chlorpropamide, glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide
Alpha-glucosidase inhibitors	Acarbose, Miglitol
Thiazolidinediones (TZD)	Pioglitazone, Rosiglitazone, Troglitazone
Meglitinides	Nateglinide, Repaglinide, Mitiglinide
Dipeptidyl peptidase-4 (DPP-4) inhibitors	Saxagliptin, Sitagliptin, Vildagliptin